The efficacy of clarithromycin in a murine model of acute toxoplasmosis was studied. Clarithromycin was administered alone and concurrently with minocycline, and eficacy was assessed by survival rates and sequential determination of parasite burden in blood, brains, and lungs. ILmited protection resulted from administration of each drug alone, whereas a remarkable synergistic effect followed concurrent administration.
The combination of pyrimethamine and sulfadiazine is the standard therapy for toxoplasmic encephalitis. However, the incidence of side effects is high; skin reaction due to the sulfonamide and hematologic toxicity due to pyrimethamine have been reported with high frequency (8) . Alternative regimens involving the replacement of one of the two components by another drug are currently being investigated. The combination of pyrimethamine plus clindamycin and the combination of pyrimethamine plus clarithromycin proved efficient for treatment of patients with toxoplasmic encephalitis (5, 7) ; other drug combinations using a macrolide have also been effective in an experimental model of acute toxoplasmosis (6) . We designed a study to identify a combination of drugs that might make the use of folate inhibitors unnecessary. Since clarithromycin and minocycline are individually active against Toxoplasma gondii (3, The treatment regimens associated with at least 50% survival by day 30 were then reevaluated by using larger groups of mice. Both survival rate and the kinetics of blood and tissue infection were evaluated. In these larger-sample experiments, mice were randomly allocated to separate groups: 30 mice served as controls (no treatment), and each treatment group consisted of 40 mice. The regimens con- Mice were studied for 30 days after infection. Monitoring of infection involved the estimation of survival rates by using the Kaplan Meier product limit method and sequential examination of parasite burden in blood, brains, and lungs on days 4, 7, 10, 14, 22, and 30 after infection; on day 30, liver and spleen tissues were also examined. At each time point, five mice from each group were sacrificed and blood and organ homogenates were cultured as described previously (12) . Briefly, serial fourfold dilutions of each blood or organ suspension were prepared in the culture medium, and then 40 ,ul of each dilution was inoculated into duplicate wells of tissue culture plates. Previous experiments using the same experimental procedure had shown that antimicrobial agents in ground tissue had no effect on parasitic growth in the cultures (12) . After the parasite burden for five mice (+ 1 standard error) was calculated for each time point.
Examination of survival rates ( Table 1 ) and culture results indicated that clarithromycin treatment at 50 mg/kg daily was ineffective in prolonging survival or reducing the parasite burden. On day 4, the parasite burdens for control mice and clarithromycin-treated mice were 5.37 ± 0.2 and 4.96 ± 0.75 log units in lungs, 1.87 ± 0.62 and 1.81 + 0.74 log units in brains and 0.6 ± 0.83 and 0.81 ± 0.74 log units in blood, respectively. Clarithromycin treatment at 200 mg/kg daily increased the mean survival time of mice, but protection was only partial, as 100% of the mice died within 18 days (Table  1) . When parasite burden was examined, parasitic infection in lungs and blood was found to decrease from day 7 while that in brains increased between days 4 and 10 (Fig. 1A) .
Minocycline treatment at 20 mg/kg daily also had limited efficacy, as 100% of the mice died within 10 days after infection, with high parasite burden in lungs (Fig. 1B) . With a dose of 50 mg/kg daily, 27% of the mice were alive on day 30 (Table 1) . When tissue cultures were studied, no parasites were detectable in blood throughout the follow-up period. In tissues, parasites were detectable only at a small number in brains on day 7 while parasite burdens in the lungs increased until day 7, became negative from day 10 to day 15, and then increased at day 22 (Fig. 1C) .
The combination of clarithromycin and minocycline was associated with marked increases in survival (Table 1) . On day 30, the survival rate was 93% for mice treated with 50 mg of clarithromycin plus 50 mg of minocycline per kg per day; it was 95% for those treated with 200 mg of clarithromycin plus 20 mg of minocycline per kg per day. The kinetics of parasite infection in blood and tissues were comparable. With both regimens, parasitemia remained undetectable. Parasite burdens decreased rapidly while mice were under treatment and, thereafter, remained at low levels in lungs and in brains ( Fig. 1D and E) . On day 30, no parasites were observed in livers; however, small numbers of parasites were observed in the spleens of two of the five mice treated with 200 mg of clarithromycin plus 20 mg of minocycline per kg per day (parasite burden = 0.6 + 0.9 log units); this was also true for two of the five mice treated with 50 mg of clarithromycin plus 50 mg of minocycline per kg per day (parasite burden = 0.8 ± 1.2 log units). For mice treated with 200 mg of clarithromycin plus 50 mg of minocycline per kg per day, survival was 100% on day 30. Throughout the follow-up, parasites remained undetectable in blood and tissues, including spleen and liver tissues, on day 30 (Fig.  1F) .
Our results confirm that minocycline alone is partially effective against murine toxoplasmosis. (1), who used a strain of lower virulence and also found 100% survival for mice treated with 200 mg of clarithromycin plus 50 mg of minocycline per kg daily; the survival rate was only 50% for mice treated with minocycline alone and 20% for those treated with clarithromycin alone. In our study, we evaluated this in vivo synergism between the two drugs by examining the parasite burden in blood and tissues of treated mice; parasites were never observed in blood or tissues when the combination of 50 mg of minocycline plus 200 mg of clarithromycin per kg daily was administered. With lower doses of either drug, the synergistic effect remained but the parasitic infection was detectable at a low level in some tissues. Since the mode of action of clarithromycin and minocycline on T. gondii is unknown, the explanation for this synergism is unclear. Our results lead us to hypothesize that the in vivo synergism reflects the complementary effect of the two drugs at the different sites of infection. Finally, these results offer a reliable experimental basis for assessing the combination of clarithromycin and minocycline in the treatment of toxoplasmosis in humans, particularly those intolerant of sulfadiazine and/or pyrimethamine. Our findings also offer a rationale for combining the two drugs for the prophylaxis of toxoplasmosis; prolonged drug efficacy, as evidenced by maintenance of low parasite burden after discontinuation of therapy, was observed in our experiments. Also, minocycline has demonstrated possible efficacy on brain cysts, as reported elsewhere (3) . Because of the antiparasitic spectrum of the two drugs (9, 10, 13) , it may be worthwhile to explore the possibilities of preventing multiple opportunistic infections. 
